Table 1.
Baseline characteristics of the study population (n = 10614)
|
Demographics
|
|
| Sex | |
| Male | 6243 (58.8%) |
| Female | 4371 (41.2%) |
| Race | |
| White | 4037 (38.0%) |
| Black | 2248 (21.2%) |
| Asian | 914 (8.6%) |
| Other/multiracial | 2942 (27.7%) |
| Unknown | 473 (4.5%) |
| Ethnicity | |
| Non-Hispanic or Latino or other/unknown | 8338 (78.6%) |
| Hispanic or Latino | 2276 (21.4%) |
| Age (yr) | 65 (54-77) |
| Body mass index (kg/m2)1 | 28.3 (24.9-32.6) |
| < 30 | 5120 (61.4%) |
| ≥ 30 | 3220 (38.6%) |
| Presence of co-morbid conditions | |
| Hypertension | 6204 (58.5%) |
| Diabetes mellitus | 3764 (35.5%) |
| Coronary artery disease | 1328 (12.5%) |
| Heart failure | 832 (7.8%) |
| Malignancy | 791 (7.5%) |
| Chronic obstructive pulmonary disease | 608 (5.7%) |
| Chronic kidney disease (stage I-IV) | 391 (3.7%) |
| End-stage renal disease | 434 (4.1%) |
| Liver chemistries (within 24 h) | |
| AST (IU/L)1 | 46 (31-72) |
| Normal | 4377 (41.3%) |
| > 1 to ≤ 4 × ULN | 5713 (53.8%) |
| > 4 to ≤ 10 × ULN | 437 (4.1%) |
| > 10 × ULN | 85 (0.8%) |
| ALT (IU/L) | 33 (21-56) |
| Normal | 4883 (46.0%) |
| > 1 to ≤ 4 × ULN | 5159 (48.6%) |
| > 4 to ≤ 10 × ULN | 484 (4.6%) |
| > 10 × ULN | 88(0.8%) |
| Alkaline phosphatase (IU/L)1 | 75 (59-98) |
| Normal | 9242 (87.1%) |
| > 1 to ≤ 4 × ULN | 1333 (12.6%) |
| > 4 to ≤ 10 × ULN | 35(0.3%) |
| > 10 × ULN | 2 (0.02%) |
| Bilirubin (mg/dL)1 | 0.5 (0.4-0.7) |
| Normal | 10119 (95.4%) |
| > 1 to ≤ 4 × ULN | 486 (4.6%) |
| > 4 to ≤ 10 × ULN | 5 (0.05%) |
| > 10 × ULN | 3 (0.03%) |
1
Missing data for some patients: Body mass index (n = 2274), alkaline phosphatase (n = 2), aspartate aminotransferase (n = 2), and bilirubin (n = 1).
Data summarized as n (%) for categorical variables and median (interquartile range) for continuous variables. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ULN: Upper limit of normal.